CEO/CFO Granted 100,000 Restricted Shares, Valued at $305K
XBIO sits 61% above its 52-week low of $1.9 on light trading volume (0.4× avg).
Summary
Xenetic Biosciences' Interim CEO and CFO, James Parslow, was granted 100,000 restricted stock shares, a significant compensation package for the nano-cap company.
Key Events · Executive and Board Changes · XBIO
-
Restricted Stock Grant to CEO/CFO
James Parslow, Interim Chief Executive Officer and Chief Financial Officer, received a grant of 100,000 restricted shares.
-
Vesting Schedule
7,000 shares vested immediately on April 21, 2026, with 31,000 shares vesting on each of the first, second, and third anniversaries of that date.
-
Change in Control Vesting
All unvested restricted stock will immediately vest upon the consummation of a Change in Control.
Analysis · XBIO · Life Sciences
This grant of 100,000 restricted shares to the Interim CEO and CFO, James Parslow, represents a substantial incentive package for Xenetic Biosciences, a nano-cap company. While such grants are standard for executive compensation, the size of this award relative to the company's current valuation is notable. The vesting schedule, with a portion vesting immediately and the remainder over three years, aims to align executive interests with long-term shareholder value, particularly as the company navigates its previously disclosed strategic review process. The provision for immediate vesting upon a change in control further incentivizes leadership to pursue potential M&A or other strategic options. Investors should monitor the potential dilutive impact of this award, especially given the company's small size.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 34.9% of the 1159 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIO was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $1.90 to $13.93. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.